Blue dye may tame dangerous immune reactions

NCT ID NCT07169487

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times

Summary

This early-stage study tests whether adding methylene blue to standard care can safely reduce cytokine release syndrome (CRS) and neurotoxicity (ICANS) in 18 adults who developed these side effects after CAR-T or bispecific antibody treatment. Participants receive methylene blue intravenously for 3–5 days, and researchers monitor side effects, immune cell levels, and cancer response. The goal is to find a safe dose and see if it helps control these serious immune reactions without harming the anti-cancer effect.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOKINE RELEASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Hematology & Blood Diseases Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.